Abstract
Introduction: Once the COVID-19 pandemic was declared, the world was waiting for the clue that would be able to cut down the progression of the disease. Vaccines play a crucial role in reducing the disease and saving many people worldwide. However, there are several side effects of these vaccines, like pain, fatigue, fever, and neurological defects like Bell’s palsy. In this systematic review, we presented evidence about the occurrence of Bell’s palsy followed by COVID-19 vaccination. Methods: We searched PubMed, SCOPUS, EBSCO, and Web of Science (WOS) from inception till October 2022. The quality assessment was conducted using the Joanna Briggs Institute, National Institute of Health, and Newcastle-Ottawa. The analysis was conducted on SPSS. Results: Thirty-five records were involved in our study. The results of our cases revealed that most of the patients (62.8%) experienced unilateral facial paralysis. Also, the majority of the cases were reported after the first dose, and most cases were after Pfizer, AstraZeneca, and Sputnik V vaccines, respectively. The patients who were treated with corticosteroids, IVIG, and anti-viral drugs, showed marked recovery afterward. Conclusion: The rate ratio of Bell’s palsy after COVID-19 vaccination was 25.3 per 1,000,000. The ratio was higher after the first dose compared to the second dose and was higher among those who took Oxford/AstraZeneca vaccine compared to other vaccines. However, this condition was reported in a small number of cases among a large number of vaccinated people worldwide. It is important to note that the benefits of getting vaccinated far outweigh any potential risks.
Keywords: COVID-19, vaccine, Bell’s palsy, side effect, systematic review
1. Introduction
Once the COVID-19 pandemic was declared, the whole world was waiting for the clue that would be able to cut down the progression of the disease. Vaccines play a crucial role in reducing the disease and saving many people worldwide. As anything could have a beneficial and harmful effect and still be used as the benefits outweigh the risks, Vaccines used but underwent multiple trials to detect safety and any adverse events trying to help people in the decision regarding using the vaccine [1]. Literature showed a wide spectrum of reported complications associated with the vaccines, either neurological, cardiovascular, cerebrovascular, etc. [2,3].
This study will deal with one of the rare neurological complications associated with different types of COVID-19 vaccination, Bell’s palsy and other disorders that mimic facial palsy. Facial nerve paralysis can be reported as isolated or a part of the autoimmune disease developed with the vaccine as Guillain-Barre syndrome (GBS), Polyneuritis or other forms of autoimmune neuropathy [4]. Bell’s palsy is an idiopathic paralysis of the facial nerve with rapid onset and underdetermined etiology diagnosed by exclusion of other causes of facial nerve paralysis. Affect population with age ranging from 15 to 50 years old and able to affect males and females equally [5].
Facial paralysis associated with Bell’s palsy, if untreated, can be spontaneously resolved within 2 months by 70%, but if managed with corticosteroids, the percentage of resolution is elevated to 90% [5]. Facial palsy shows reported to be 25 cases per 100,000 per year in the general population, and Yellow card reporting systems in the United Kingdom (UK) have recorded 291 cases of facial paralysis with the Pfizer vaccine from 9 December 2020 to 5 April 2021. Although it is shown to be high, the MHRA says it is not higher than that of the general population [6]; therefore, continuous monitoring of the side effects is important. The three major vaccines in the UK, Moderna, AstraZeneca and Pfizer/BioTech, reported facial nerve palsy in their initial trials [7,8]. In the phase 3 trial of the Pfizer/BioTech vaccine, over 38,000 patients showed four cases of Bell’s palsy compared to zero reported cases in the placebo group [8]. The UK government’s website considered facial paralysis as a potential side effect of the Pfizer/BioTech vaccine; therefore, reporting cases of facial paralysis associated with the Pfizer/BioTech vaccine is important to support or exclude this theory [8].
In the phase 3 trial, safety analysis of the Moderna vaccine conducted over 30,420 patients also reported four cases of Bell’s palsy, three from the vaccine group and only one from the placebo group, while the Oxford/Astrazeneca vaccine trial conducted in over 23,745 participants reported six cases, three from vaccine group and three from the placebo group [9]. Therefore, monitoring cases of facial paralysis associated with different types of vaccines is important to detect the possible relationship between the vaccine and facial palsy. All reported cases showed the association without any causal relationship, and the U.S. Food and Drug Administration (FDA) recommends continuous monitoring to detect any possible side effects associated with the vaccines. Our study aimed to conclude and analyze the available evidence in the literature to help the researches to formulate the next research questions and continue monitor of the associated side effects with different types of the vaccine and even monitor unilateral facial nerve palsy and also help the clinicians to take the decision regarding the vaccine administration to different population taking in consideration the risks and benefits.
Recent studies suggested further evaluation of bell’s palsy and COVID-19 vaccination, and till now, there has been no strong evidence that can confidently conclude whether there is an association between bell’s palsy and COVID-19 vaccinations or not [10,11]. Furthermore, a systematic review of 17 studies was published to investigate the existence and development of COVID-19 symptoms after vaccinations [12]. They concluded that COVID-19 vaccination before SARS-COV-2 infection could reduce the risk of long-term symptoms of COVID-19.
Therefore, our aim is to specifically and comprehensively pool all records that reported the occurrence and characteristics of Bell’s Palsy after COVID-19 vaccinations.
2. Methods
We followed the guidelines of the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) when conducting this systematic review and meta-analysis. Also, this investigation was registered in the International Prospective Registration of Systematic Reviews (PROSPERO) database; [registration ID: CRD42023389393].
2.1. Literature Search Strategy
We searched PubMed, SCOPUS, EBSCO, and Web of Science from inception till October 2022. Our search strategy comprised: [ (COVID-19 OR “SARS-COV-2” OR “corona virus-19” OR “COVID-19 vaccines” OR “SARS-COV-2 vaccines” OR “ChAdOx1 nCoV-19 vaccine” OR “Astra- 89 Zeneca Vaccine” OR “Ad26.COV2. S” OR “Johnson & Johnson Vaccine”) AND (“bell palsy” OR “facial paralysis” OR “bell’s pals*” OR “acute inflammatory facial neuropathy)]. To broaden the literature search, we scanned the reference lists for eligible studies and contemporary reviews for potentially missed records. The study selection process comprised omitting duplicate records, followed by TITLE/ABSTRACT screening, then concluded by FULL-TEXT screening. Two independent co-authors completed this task, and any disagreements were solved by the primary investigators.
2.2. Eligibility Criteria and Study Selection
Studies achieving our inclusion and exclusion criteria were included: we included studies that reported (i) patients underwent any kind of COVID-19 vaccination, (ii) both genders and all age groups, (iii) the incidence and characteristics of bell’s palsy after COVID-19 vaccination, (iv) with the following study designs: case reports and case series, observational studies, and clinical trials. We excluded (i) animal, laboratory, in vitro studies, conferences, reviews, and book chapters and (ii) studies that did not mention bell’s palsy as an event.
2.3. Data Extraction
We extracted the data from each included study using a pre-specified uniform data extraction sheet. The extracted data included the following domains: study design, the number of included patients, age, sex, comorbidities, main signs and symptoms, the type of vaccine received and the number of doses, onset of fascial palsy, diagnostic tools, treatments, follow up duration and prognosis.
2.4. Quality Assessment
We have implanted the Joanna Briggs Institute (JBI) [13] and National Institute of Health (NIH) [14] quality assessment tools for our included Case reports and case series, respectively, based on the clinical characteristics, history, diagnostics, interventions and management plans with evidence score ranging from Poor, Fair or Good. Newcastle-Ottawa (NOS) [15] tool for included observational studies Cohort, Case-control and Cross-sectional studies based on selection, comparability and Outcome domains. Quality assessment is done aiming to estimate the overall evidence that our study deals with. Two Authors independently assessed the evidence and to remove the conflicts.
2.5. Statistical Analysis
The statistical analysis was conducted on SPSS. Number and percentages were used to describe the categorical variables, as well as mean and standard deviation (SD) was used to describe the continuous variables.
3. Results
After searching different databases, we obtained 430 records. After removing the duplication, 305 records underwent the first screening. Of them, 52 reports were included. (Figure 1.)
Figure 1.
Shows the PRISMA flow diagram of the included studies.
This systematic review included cohort (n = 13), case-control (n = 3), cross-sectional studies (n = 3) and self-controlled case series (n = 2) that described the rate ratio of Bell’s palsy after administration of COVID-19 vaccines. Further, this review included case reports (n = 23) and case series (n = 8), which described patients developing events of Bell’s palsy after COVID-19 vaccination (n = 105). The majority of cases were men (57.1%). The age of the patients varied from approximately 30–60 years; the average age of patients was 49.7 ± 23.2 years. The most common comorbidity among the included patients was hypertension (24.8%), followed by diabetes (16.2%) and heart failure (4.8%). According to the administrated vaccines, 49 patients took Pfizer (46.7%), while 22 (21%) and 16 (15.3%) of the cases took Sinovac Biotech and AstraZeneca, respectively. Most cases developed the symptoms after the first dose of vaccines (35.2%). The average time to symptom onset after the vaccination was 11.6 days. The majority of cases took prednisolone (38.5%). Regarding the prognosis, 36 cases (69.2%) have recovered (26 completely and 13 partially). More details can be seen in Table 1. The main clinical and pathological characteristics of the patients included in our study were summarized in Supplementary File 1, Table S7. The characteristics of the cohort, case-control, cross-sectional studies, and self-controlled case series included in this review were presented in Supplementary File 1, Table S8.
Table 1.
Characteristics of the patients.
| Frequency (n) | Percentage (%) | ||
|---|---|---|---|
| Characteristics (n = 105) | |||
| Age, mean (SD) | 49.7 (23.2) | ||
| Sex | Male | 60 | 57.1 |
| Female | 45 | 42.9 | |
| Comorbidities | |||
| Chronic kidney disease | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| HIV | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Diabetes | NA | 49 | 46.7 |
| No | 39 | 37.1 | |
| Yes | 17 | 16.2 | |
| Hypertension | NA | 46 | 43.8 |
| No | 33 | 31.4 | |
| Yes | 26 | 24.8 | |
| Dyslipidemia | NA | 11 | 10.5 |
| No | 91 | 86.7 | |
| Yes | 3 | 2.8 | |
| Asthma | NA | 11 | 10.5 |
| No | 92 | 87.6 | |
| Yes | 2 | 1.9 | |
| Migraine | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Hyperuricemia | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Obesity | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Heart failure | NA | 59 | 56.2 |
| No | 41 | 39 | |
| Yes | 5 | 4.8 | |
| Thyroid dysfunction | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Cancer | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Poliomyelitis | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Stroke | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Obstructive sleep apnea | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Meniere’s disease | NA | 11 | 10.5 |
| No | 93 | 88.6 | |
| Yes | 1 | 0.9 | |
| Vaccines | |||
| Type of given vaccine | NA | 1 | 0.9 |
| Moderna | 6 | 5.7 | |
| Pfizer | 49 | 46.7 | |
| AstraZeneca | 16 | 15.3 | |
| Sinovac Biotech | 22 | 21 | |
| Johnson & Johnson | 2 | 1.9 | |
| Sputnik V | 7 | 6.7 | |
| Vector based vaccine | 1 | 0.9 | |
| COVAXIN | 1 | 0.9 | |
| Doses | |||
| Dosage resulted in the symptoms | NA | 57 | 54.3 |
| 1 | 37 | 35.2 | |
| 2 | 11 | 10.5 | |
| Diagnostic tools, treatments, and prognosis (n = 52) | |||
| Diagnostic tools | |||
| Physical examination | NA | 1 | 1.9 |
| No | 2 | 3.8 | |
| Yes | 49 | 94.2 | |
| CT | No | 44 | 84.6 |
| Yes | 8 | 15.4 | |
| MRI | No | 23 | 44.2 |
| Yes | 29 | 55.8 | |
| EMG | No | 46 | 88.5 |
| Yes | 6 | 11.5 | |
| Nerve conduction | No | 47 | 90.4 |
| Yes | 5 | 9.6 | |
| Lumbar puncture | No | 31 | 59.6 |
| Yes | 21 | 40.4 | |
| Electrophoresis | NA | 1 | 1.9 |
| No | 39 | 75 | |
| Yes | 12 | 23.1 | |
| Treatments | |||
| Prednisone | NA | 11 | 21.2 |
| No | 21 | 40.4 | |
| Yes | 20 | 38.5 | |
| Methylprednisolone | NA | 11 | 21.2 |
| No | 38 | 73.1 | |
| Yes | 3 | 5.8 | |
| Deflazacort | NA | 11 | 21.2 |
| No | 40 | 76.9 | |
| Yes | 1 | 1.9 | |
| IVIG | NA | 11 | 21.2 |
| No | 27 | 51.9 | |
| Yes | 14 | 26.9 | |
| Anti-viral | NA | 11 | 21.2 |
| No | 34 | 65.4 | |
| Yes | 7 | 13.5 | |
| Plasma exchange | NA | 11 | 21.2 |
| No | 40 | 76.9 | |
| Yes | 1 | 1.9 | |
| Follow-up time, mean (SD) | 30.19 (72.55) | ||
| Outcome | |||
| The affected side of the face | Unilateral | 36 | 69.2 |
| Bilateral | 16 | 30.8 | |
| Time of symptoms onset (days), mean (SD) | 11.6 (11.13) | ||
| Prognosis | NA | 12 | 21.2 |
| No response | 5 | 9.6 | |
| Partial response | 13 | 25 | |
| Complete response | 23 | 44.2 | |
| Overall prognosis | NA | 12 | 21.2 |
| Not Recovered | 5 | 9.6 | |
| Recovered | 36 | 69.2 | |
According to Table 2, the percentage of recovered females was slightly higher than recovered males (92.9% and 88.5%, respectively). All the cases who developed Bell’s palsy after the second dose recovered, while only 90% recovered among those who developed this condition after the first dose. Non-hypertensive individuals recovered at a higher rate (100%) than hypertensive ones (50%).
Table 2.
Represents the possible factors affecting the prognosis of the COVID-19 vaccine-induced Bell’s palsy (n = 40).
| Characteristics | Not Recovered n (%) | Recovered n (%) | |
|---|---|---|---|
| Gender | |||
| Male | 3 (11.5) | 23 (88.5) | |
| Female | 1 (7.1) | 13 (92.9) | |
| Age | |||
| <40 | 1 (6.7) | 14 (93.3) | |
| ≥40 | 3 (12) | 22 (88) | |
| Affected side | |||
| Unilateral | 1 (4.2) | 23 (95.8) | |
| Bilateral | 3 (18.8) | 13 (81.3) | |
| Doses | |||
| The dose that led to the symptoms | |||
| NA | 1 (25) | 3 (75) | |
| First | 3 (10) | 27 (90) | |
| Second | 0 (0.0) | 6 (100) | |
| Vaccines | |||
| Type of vaccine | |||
| NA | 0 (0.0) | 1 (100) | |
| Moderna | 0 (0.0) | 5 (100) | |
| Pfizer | 1 (8.3) | 11 (91.7) | |
| AstraZeneca | 2 (18.2) | 9 (81.8) | |
| Sinovac Biotech | 0 (0.0) | 1 (100) | |
| Johnson & Johnson | 0 (0.0) | 1 (100) | |
| Sputnik V | 1 (14.3) | 6 (85.7) | |
| Vector based vaccine | 0 (0.0) | 1 (100) | |
| COVAXIN | 0 (0.0) | 1 (100) | |
| Comorbidities | |||
| Chronic Kidney disease | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| HIV | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Diabetes | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Hypertension | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 0 (0.0) | 25 (100) | |
| Yes | 2 (50) | 2 (50) | |
| Dyslipidemia | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Asthma | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Migraine | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Hyperuricemia | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 1 (3.6) | 27 (96.4) | |
| Yes | 1 (100) | 0 (0.0) | |
| Obesity | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Heart disease | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Thyroid dysfunction | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Cancer | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Poliomyelitis | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (7.1) | 26 (92.9) | |
| Yes | 0 (0.0) | 1 (100) | |
| Stroke | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Obstructive sleep apnea | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Meniere’s disease | |||
| NA | 2 (18.2) | 9 (81.8) | |
| No | 2 (6.9) | 27 (93.1) | |
| Treatments | |||
| Prednisone | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 3 (15) | 17 (85) | |
| Yes | 1 (5.6) | 17 (94.4) | |
| Methylprednisolone | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (11.4) | 31 (88.6) | |
| Yes | 0 (0.0) | 3 (100) | |
| Deflazacort | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (10.8) | 33 (89.2) | |
| Yes | 0 (0.0) | 1 (100) | |
| IVIG | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 2 (8.3) | 22 (91.7) | |
| Yes | 2 (14.3) | 12 (85.7) | |
| Anti-viral | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (12.5) | 28 (87.5) | |
| Yes | 0 (0.0) | 6 (100) | |
| Plasma exchange | |||
| NA | 0 (0.0) | 2 (100) | |
| No | 4 (10.8) | 33 (89.2) | |
| Yes | 0 (0.0) | 1 (100) | |
According to Figure 2, the rate ratio of Bell’s palsy among vaccinated groups was 25.3 per 1,000,000. The ratio was higher after the first dose compared to the second dose (Rate Ratio = 171.2 and 42.1, respectively). Patients who took the Oxford/AstraZeneca vaccine revealed higher ratios (Rate Ratio = 178.6) compared to other identified vaccines.
Figure 2.
Represents the frequency of Bell’s palsy per 1,000,000 individuals after COVID-19 vaccination.
Quality Assessment
The overall quality assessment of the 24 included case reports based on the JBI checklist ranged from moderate to high evidence, with 17 case reports showing a low risk of bias and seven studies with a moderate risk of bias supporting their inclusion based on JBI recommendations, as shown in Table 3. The risk of bias assessment of the seven included case series based on NIH scores revealed six studies with fair-quality evidence and one with good evidence, as shown in Supplementary File 2, Table S2. The assessment of the included 15 cohort studies showed eight studies with good evidence, one with fair evidence and seven with poor evidence based on the NOS scale modified for cohort studies, as shown in Supplementary File 1, Table S3. The included seven case controls show one with fair evidence and six with high-quality evidence based on the NOS scale, as shown in Supplementary File 1, Table S4. All the included cross-sectional studies show good-quality evidence, as shown in Supplementary File 1, Table S5.
Table 3.
The quality assessment of the included case reports using the (JBI) Quality Assessment Tool.
| Study ID | The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Case Reports | Total Quality Score, (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Q (1) | Q (2) | Q (3) | Q (4) | Q (5) | Q (6) | Q (7) | Q (8) | ||
| Burrows 2021 [16] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Cellina 2022 [17] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Čenščák 2021 [18] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Cirillo 2022 [19] | NO | NO | YES | YES | YES | YES | NO | YES | 62.50% |
| Colella 2021 [20] | YES | YES | YES | NO | YES | YES | NO | YES | 75% |
| Ercoli 2021 [2] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Finsterer 2021 [21] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Iftikhar 2021 [22] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Introna 2021 [23] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Ish 2021 [24] | YES | NO | YES | NO | YES | YES | NO | YES | 62.50% |
| Manea 2021 [25] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Martin-Villares 2021 [26] | NO | YES | YES | YES | NO | YES | NO | YES | 75% |
| Mason 2021 [27] | YES | NO | YES | YES | YES | YES | NO | YES | 75% |
| Mussatto2021 [28] | YES | NO | YES | YES | YES | YES | NO | YES | 75% |
| Nasuelli 2021 [29] | YES | NO | YES | YES | YES | YES | NO | YES | 75% |
| Nishizawa 2021 [30] | YES | YES | YES | YES | NO | NO | NO | YES | 62.50% |
| Obermann 2021 [31] | YES | YES | YES | YES | YES | YES | NO | YES | 88% |
| Pothiawala 2021 [32] | YES | YES | YES | NO | YES | NO | NO | YES | 62.50% |
| Poudel 2022 [33] | YES | NO | YES | YES | YES | YES | NO | YES | 75% |
| Repajic 2021 [34] | YES | YES | YES | NO | YES | YES | NO | YES | 75% |
| Shalabi 2022 [35] | YES | NO | YES | YES | YES | YES | NO | YES | 75% |
| Yu 2021 [36] | YES | NO | YES | YES | YES | YES | NO | YES | 75% |
| Zhang 2022 [37] | YES | NO | YES | NO | YES | YES | NO | YES | 62.50% |
4. Discussion
4.1. Summary of the Findings
An increasing incidence of neurological disorders has escalated following COVID-19 vaccine administrations among the general population [38]. Bell’s palsy is one of these neuropathies that may have a close relationship with COVID-19 vaccines [39]. The results of our cases revealed that most of the patients (62.8%) experienced unilateral facial paralysis. The majority of the cases were reported after the first dose, and most cases were after Pfizer, AstraZeneca and Sputnik V vaccines, respectively. According to the diagnostic measures, the physical examination, MRI, and lumbar puncture were the most used in the included studies. The patients who were treated with corticosteroids, IVIG, and antiviral drugs, showed marked recovery afterward. Hypertension was the most common comorbidity among the included patients. In addition, there was a statistically significant difference between prognosis and blood pressure status.
The exact mechanism of developing facial nerve palsy following COVID-19 vaccination is yet to be unclear [40]. Multiple theories suggest the possible pathophysiology behind this phenomenon. One theory suggests the involvement of autoimmune processes either via mimicry of host molecules by the vaccine antigens or by bystander activation of autoreactive dormant T-cells [17,41]. Moreover, a study regarding the immunological activities after COVID-19 vaccine administration showed that a significant increase of antibody titers occurs following the two doses of the BNT162b2 vaccine [42]. This huge stimulation of the immune system might as well contribute to the development of Bell’s palsy [43]. Another theory states that the reactivation of different dormant viruses in the CNS might cause palsy. These viruses include the varicella-zoster virus, the Usutu virus, human herpesvirus 6 and herpes simplex virus type 1 (HSV-1). It is understood that perturbation of type I IFN signaling could lead to reactivation of the latent herpes simplex infection in neurons near the geniculate ganglion, which may prompt facial palsy (3;4). When type I IFN signaling is flawed, as it is done after vaccination with SARS-CoV-2, the capability of CD8+ T cells to retain herpes under control would also be damaged. The reactivation of HSV-1 is probably the most accepted theory [33]. A study involving 14 patients with Bell’s palsy, nine with Ramsy–Hunt syndrome, and 14 control patients, managed to show a link between the presence of the HSV-1 genome in patients and the development of Bell’s palsy [17]. In addition, it is worth mentioning that the influenza vaccine has been previously linked to an increased incidence of Bell’s palsy. The mechanism of this was also thought to be the reactivation of latent HSV-1 in the geniculate ganglion of the facial nerve, which in turn caused inflammation of the nerve [16,44]. Based on several hypotheses, the interaction between elements of the vaccine and specific human proteins’ immune cross-reactivity consequences in autoimmune disease, which may cause Bell’s palsy [45]. Innate immunity could be activated by the vaccine’s mRNA and lipids, which induce the synthesis of interferons and possibly damage the myelin sheath [41,46]. This theory was further supported by the fact that interferon therapy in hepatitis C infection patients indeed showed a rare but evident occurrence of Bell’s palsy [46,47,48]. Nevertheless, it is important to mention that Bell’s palsy can also happen secondary to GBS or other demyelinating disorders since these disorders are rare but possible adverse effects following COVID-19 vaccination [40,43]. After all, we can say that the pathophysiology of such a phenomenon could be caused by multiple factors at once and may differ from person to person, given the fact that most reported cases of Bell’s palsy after COVID-19 vaccination either show differences in the time of onset or the severity of symptoms presented [40,43].
In previous systematic reviews conducted by Shahsavarinia et al. [10] and Khurshid et al. [49], the most notable comorbidities identified among these studies were hypertension followed by diabetes and dyslipidemia, which is consistent with our study. At the same time, in the current study, we conducted the analytical test to determine the discrepancy between the variables and prognosis. Although there was no statistically significant difference concerning the prognosis and most of the comorbidities, patients without hyperuricemia or hypertension had a high rate of full recuperation in comparison with patients with these diseases. Our findings are in the same direction as the former reviews performed by Sriwastava et al. [50] and Shahsavarinia et al. [10] in terms of the association between the type of vaccines and the incidence of facial palsy. Unlikely, Khurshid et al. [49] reported that most of the cases had bell’s palsy after taking the AstraZeneca vaccine. This could be elucidated by the variation in sample size and baseline characteristics. However, our results are in agreement with Khurshid et al. [49] in the case that the majority of symptoms have appeared following the first dose of the vaccines.
The average time from vaccination to onset of symptoms amongst the cases in our review was 11.49 (11.064) days. This is consistent with previous studies by Shahsavarinia et al. [10] that mentioned the onset of symptoms of bell’s palsy at around 10 days post-vaccination. On the other hand, our study represented that (62.8%) of the patients had unilateral-side complaints. As evidenced by Khurshid et al. [49], most of the patients (53.45%) presented with bilateral facial weakness.
Diagnosis of any facial palsy cases is often based on physical examination and is confirmed through electromyography, lumbar puncture, CT, and MRI. In our systematic review, (95.35%) of the cases were diagnosed through physical examination, (67.44%) using MRI, and (48.84%) by lumbar puncture. In contrast, Khurshid et al. [49] study documented the majority of the included patients were diagnosed by CSF analysis and then by CT and MRI. This can be attributed to the fact that most participants in this study may have different characteristics from Khurshid et al. study [49]. Regarding the management, (46.51%) and (32.5%) of the patients in our study who received corticosteroids and IVIG therapy, respectively, have more quick mitigation of the symptoms. This result was also identified in another systematic review by Khurshid et al. [49].
Generally, the incidence of neurological diseases after vaccination varies depending on demographic features, residual confounding, type of vaccines, and reporting bias that may have a potential impact on the consequences [51]. It is critical to highlight that the causality relationship between Bell’s palsy and COVID-19 vaccines is not confirmed yet. Therefore, we recommend conducting further studies in an attempt to conclude the possibility of synergistic influence between facial palsy and COVID-19 vaccines.
4.2. Limitations and Strengths of the Study
The major limitations in this study have been related to a limited number of included studies that assessed the association between facial palsy and COVID-19 vaccines. Hence, the small sample size, which is reflected in the strength of the evidence. Nevertheless, the strengths of our study are as follows: (1) our systematic review provided the analytical investigation between the variables and prognosis of patients with bell’s palsy after commencing the vaccination, (2) we provided a more comprehensive analysis in an attempt to summarize the probability association between COVID-19 vaccines and facial palsy.
5. Conclusions
The rate ratio of Bell’s palsy after COVID-19 vaccination was 25.3 per 1,000,000. The ratio was higher after the first dose compared to the second dose and was higher among those who took the Oxford/AstraZeneca vaccine compared to other vaccines. The average time to symptom onset after the vaccination was 11.6 days. Hypertension was the most common comorbidity among the included patients. Moreover, prednisone was the most frequent drug used to manage this condition. Overall, the majority of the patients recovered. However, this condition was reported in a small number of cases among a large number of vaccinated people worldwide. Additionally, it is important to note that the COVID-19 vaccine has been shown to be safe and effective in preventing illness as well as the benefits of getting vaccinated far outweigh any potential risks.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines11020236/s1. Table S1: the quality assessment of included case reports using the (JBI) Quality Assessment Tool. Table S2: the quality assessment of included case series studies using the (NIH) Quality Assessment Tool. Table S3: the quality assessment of included self-controlled case series studies using the (NIH) Quality Assessment Tool. Table S4: the quality assessment of included cohort studies using the (NOS) Quality Assessment Tool. Table S5: the quality assessment of included case-control studies using the (NOS) Quality Assessment Tool. Table S6: the quality assessment of included cross-sectional studies using the (NOS) Quality Assessment Tool. Table S7: the main clinical and pathological characteristics of the included patients. Table S8: the characteristics of the cohort, case-control, and cross-sectional studies and self-controlled case series included in our systematic review.
Author Contributions
Conceptualization, K.A., E.A. and A.N.; methodology, K.A., A.K., H.A., O.S., M.A.-H., S.C. and R.A.D.; software, K.A. and A.N.; validation, K.A., E.A. and A.N.; formal analysis, K.A. and A.N.; investigation, K.A., A.K., H.A., O.S., M.A.-H., S.C., R.A.D. and E.A.; resources, A.K. and S.C.; data curation, K.A., A.K., H.A., O.S., M.A.-H., S.C., R.A.D., E.A. and A.N.; writing—original draft preparation, K.A., A.K., H.A., O.S., M.A.-H., S.C., R.A.D., E.A. and A.N.; writing—review and editing, E.A. and A.N.; visualization, A.N.; supervision, E.A. and A.N.; project administration, K.A. and E.A.; funding acquisition. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable because this study based on published records.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Funding Statement
All authors declare they receive no fund.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.COVID-19 Vaccine AstraZeneca: Benefits Still Outweigh the Risks Despite Possible Link to Rare bBlood cClots with Low Blood Platelets | European Medicines Agency. [(accessed on 19 December 2022)]. Available online: https://www.ema.europa.eu/en/news/COVID-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.
- 2.Ercoli T., Lutzoni L., Orofino G., Muroni A., Defazio G. Functional neurological disorder after COVID-19 vaccination. Neurol. Sci. 2021;42:3989–3990. doi: 10.1007/s10072-021-05504-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Garg R.K., Paliwal V.K. Spectrum of neurological complications following COVID-19 vaccination. Neurol. Sci. 2022;43:3–40. doi: 10.1007/s10072-021-05662-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hampton L.M., Aggarwal R., Evans S.J.W., Law B. General determination of causation between COVID-19 vaccines and possible adverse events. Vaccine. 2021;39:1478–1480. doi: 10.1016/j.vaccine.2021.01.057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Zandian A., Osiro S., Hudson R., Ali I.M., Matusz P., Tubbs S.R., Loukas M. The neurologist’s dilemma: A comprehensive clinical review of Bell’s palsy, with emphasis on current management trends. Med. Sci. Monit. 2014;20:83–90. doi: 10.12659/MSM.889876. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.The Pfizer BioNTech (BNT162b2) COVID-19 Vaccine: What yYou Need to Know. [(accessed on 19 December 2022)]. Available online: https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-COVID-19--vaccine-what-you-need-to-know.
- 7.Regulatory Approval of COVID-19 Vaccine AstraZeneca - GOV.UK. [(accessed on 19 December 2022)]; Available online: https://www.gov.uk/government/publications/regulatory-approval-of-COVID-19-vaccine-astrazeneca.
- 8.ARCHIVE: Information for UK recipients on Pfizer/BioNTech COVID-19 vaccine (Regulation 174) - GOV.UK. [(accessed on 19 December 2022)]; Available online: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-COVID-19/information-for-uk-recipients-on-pfizerbiontech-COVID-19-vaccine.
- 9.Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. COVE Study Group Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Shahsavarinia K., Mahmoodpoor A., Sadeghi-Ghyassi F., Nedayi A., Razzaghi A., Zehi Saadat M., Salehi-Pourmehr H. Bell’s Palsy and COVID-19 Vaccination: A Systematic Review. Med. J. Islam. Repub. Iran. 2022;36:85. doi: 10.47176/mjiri.36.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cirillo N., Doan R. The association between COVID-19 vaccination and Bell’s palsy. Lancet Infect. Dis. 2022;22:5–6. doi: 10.1016/S1473-3099(21)00467-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Peligro P.J., Casimiro M., Guerrero J.J., Gellaco M.M.L., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for... | Download Scientific Diagram. [(accessed on 19 December 2022)]. Available online: https://www.researchgate.net/figure/The-Joanna-Briggs-Institute-JBI-critical-appraisal-checklist-for-studies-reporting_fig2_322317583.
- 14.NIH Quality Assessment Tool for Case Series/Case Reports | Download Scientific Diagram. [(accessed on 19 December 2022)]. Available online: https://www.researchgate.net/figure/NIH-quality-assessment-tool-for-case-series-case-reports_tbl3_344087387.
- 15.Ottawa Hospital Research Institute. [(accessed on 19 December 2022)]. Available online: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
- 16.Burrows A., Bartholomew T., Rudd J., Walker D. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses. BMJ Case Rep. 2021;14 doi: 10.1136/bcr-2021-243829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Cellina M., D’Arrigo A., Floridi C., Oliva G., Carrafiello G. Left Bell’s palsy following the first dose of mRNA-1273 SARS-CoV-2 vaccine: A case report. Clin. Imaging. 2022;82:1–4. doi: 10.1016/j.clinimag.2021.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Čenščák D., Ungermann L., Štětkářová I., Ehler E. Guillan-Barré Syndrome after First Vaccination Dose against COVID-19: Case Report. Acta Medica (Hradec Kralove) 2021;64:183–186. doi: 10.14712/18059694.2021.31. [DOI] [PubMed] [Google Scholar]
- 19.Cirillo N., Orlandi M., Colella G. Patients with post-COVID-19 vaccination facial palsy: To boost or not to boost? Transl. Neurosci. 2022;13:236–239. doi: 10.1515/tnsci-2022-0240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Colella G., Orlandi M., Cirillo N. Bell’s palsy following COVID-19 vaccination. J. Neurol. 2021;268:3589–3591. doi: 10.1007/s00415-021-10462-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Finsterer J. Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination. Case Rep. Infect. Dis. 2021;2021:3619131. doi: 10.1155/2021/3619131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Iftikhar H., Noor S.M.U., Masood M., Bashir K. Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine. Cureus. 2021;13:e15935. doi: 10.7759/cureus.15935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Introna A., Caputo F., Santoro C., Guerra T., Ucci M., Mezzapesa D.M., Trojano M. Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association? Clin. Neurol. Neurosurg. 2021;208:106887. doi: 10.1016/j.clineuro.2021.106887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ish S., Ish P. Facial nerve palsy after COVID-19 vaccination - A rare association or a coincidence. Indian J. Ophthalmol. 2021;69:2550–2552. doi: 10.4103/ijo.IJO_1658_21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Manea M.M., Dragoș D., Enache I., Sirbu A.G., Tuta S. Multiple cranial nerve palsies following COVID-19 vaccination-Case report. Acta Neurol. Scand. 2022;145:257–259. doi: 10.1111/ane.13548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Martin-Villares C., Vazquez-Feito A., Gonzalez-Gimeno M.J., de la Nogal-Fernandez B. Bell’s palsy following a single dose of mRNA SARS-CoV-2 vaccine: A case report. J. Neurol. 2022;269:47–48. doi: 10.1007/s00415-021-10617-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Mason M.C., Liaqat A., Morrow J., Basso R., Gujrati Y. Bilateral Facial Nerve Palsy and COVID-19 Vaccination: Causation or Coincidence? Cureus. 2021;13:e17602. doi: 10.7759/cureus.17602. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Mussatto C.C., Sokol J., Alapati N. Bell’s palsy following COVID-19 vaccine administration in HIV+ patient. Am. J. Ophthalmol. Case Rep. 2022;25:101259. doi: 10.1016/j.ajoc.2022.101259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Nasuelli N.A., De Marchi F., Cecchin M., De Paoli I., Onorato S., Pettinaroli R., Savoini G., Godi L. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. Neurol. Sci. 2021;42:4747–4749. doi: 10.1007/s10072-021-05467-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Nishizawa Y., Hoshina Y., Baker V. Bell’s palsy following the Ad26.COV2.S COVID-19 vaccination. QJM. 2021;114:657–658. doi: 10.1093/qjmed/hcab143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Obermann M., Krasniqi M., Ewers N., Fayad J., Haeberle U. Bell’s palsy following COVID-19 vaccination with high CSF antibody response. Neurol. Sci. 2021;42:4397–4399. doi: 10.1007/s10072-021-05496-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Pothiawala S. Bell’s Palsy After Second Dose of Moderna COVID-19 Vaccine: Coincidence or Causation? Acta Med. Litu. 2021;28:298–301. doi: 10.15388/Amed.2021.28.2.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Poudel S., Nepali P., Baniya S., Shah S., Bogati S., Nepal G., Ojha R., Edaki O., Lazovic G., Kara S. Bell’s palsy as a possible complication of mRNA-1273 (Moderna) vaccine against COVID-19. Ann. Med. Surg. 2022;78:103897. doi: 10.1016/j.amsu.2022.103897. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Repajic M., Lai X.L., Xu P., Liu A. Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav. Immun. Health. 2021;13:100217. doi: 10.1016/j.bbih.2021.100217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Shalabi F., Lossos A., Karussis D. A case report of unilateral cervical lymphadenopathy and multiple cranial neuropathies following mRNA-COVID-19 vaccination. BMC Neurol. 2022;22:369. doi: 10.1186/s12883-022-02900-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Yu B.-Y., Cen L.-S., Chen T., Yang T.-H. Bell’s palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell’s palsy: A case report. World J. Clin. Cases. 2021;9:8274–8279. doi: 10.12998/wjcc.v9.i27.8274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Zhang H., Sanchez Gomez D., Repajic M., Liu A.K. Another Case of Bell’s Palsy Recurrence After Pfizer-BioNTech COVID-19 Vaccination. Cureus. 2022;14:e27422. doi: 10.7759/cureus.27422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Dutta S., Kaur R., Charan J., Bhardwaj P., Ambwani S.R., Babu S., Goyal J.P., Haque M. Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines. Cureus. 2022;14:e21376. doi: 10.7759/cureus.21376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Renoud L., Khouri C., Revol B., Lepelley M., Perez J., Roustit M., Cracowski J.-L. Association of Facial Paralysis With mRNA COVID-19 Vaccines: A Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database. JAMA Intern. Med. 2021;181:1243–1245. doi: 10.1001/jamainternmed.2021.2219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Wan E.Y.F., Chui C.S.L., Lai F.T.T., Chan E.W.Y., Li X., Yan V.K.C., Gao L., Yu Q., Lam I.C.H., Chun R.K.C., et al. Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: A case series and nested case-control study. Lancet Infect. Dis. 2022;22:64–72. doi: 10.1016/S1473-3099(21)00451-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ozonoff A., Nanishi E., Levy O. Bell’s palsy and SARS-CoV-2 vaccines. Lancet Infect. Dis. 2021;21:450–452. doi: 10.1016/S1473-3099(21)00076-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Khoury D.S., Cromer D., Reynaldi A., Schlub T.E., Wheatley A.K., Juno J.A., Subbarao K., Kent S.J., Triccas J.A., Davenport M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:1205–1211. doi: 10.1038/s41591-021-01377-8. [DOI] [PubMed] [Google Scholar]
- 43.Wan E.Y.F., Chui C.S.L., Ng V.W.S., Wang Y., Yan V.K.C., Lam I.C.H., Fan M., Lai F.T.T., Chan E.W.Y., Li X., et al. mRNA (BNT162b2) COVID-19 vaccination increased risk of Bell’s palsy: A nested case control and self-controlled case series study. Clin. Infect. Dis. 2022 doi: 10.1093/cid/ciac460. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Ahsanuddin S., Nasser W., Roy S.C., Povolotskiy R., Paskhover B. Facial paralysis and vaccinations: A vaccine adverse event reporting system review. Fam. Pract. 2022;39:80–84. doi: 10.1093/fampra/cmab068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Seneff S., Nigh G., Kyriakopoulos A.M., McCullough P.A. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem. Toxicol. 2022;164:113008. doi: 10.1016/j.fct.2022.113008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Bekkali N., Allard T., Lengellé C., Estève E. Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine. Therapie. 2021;76:364–365. doi: 10.1016/j.therap.2021.04.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Hwang I., Calvit T.B., Cash B.D., Holtzmuller K.C. Bell’s palsy: A rare complication of interferon therapy for hepatitis C. Dig. Dis. Sci. 2004;49:619–620. doi: 10.1023/B:DDAS.0000026389.56819.0c. [DOI] [PubMed] [Google Scholar]
- 48.Shemer A., Pras E., Einan-Lifshitz A., Dubinsky-Pertzov B., Hecht I. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA Otolaryngol. Head Neck Surg. 2021;147:739–743. doi: 10.1001/jamaoto.2021.1259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Khurshid M., Ansari I., Ahmad H., Ghaffar H., Khurshid A., Shahid A., Essar M.Y., Ullah I., Cheema H.A. Development of facial palsy following COVID-19 vaccination: A systematic review. Ann. Med. Surg. (Lond.) 2022;82:104758. doi: 10.1016/j.amsu.2022.104758. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Sriwastava S., Sharma K., Khalid S.H., Bhansali S., Shrestha A.K., Elkhooly M., Srivastava S., Khan E., Jaiswal S., Wen S. COVID-19 Vaccination and Neurological Manifestations: A Review of Case Reports and Case Series. Brain Sci. 2022;12:407. doi: 10.3390/brainsci12030407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Noseda R., Ripellino P., Ghidossi S., Bertoli R., Ceschi A. Reporting of Acute Inflammatory Neuropathies with COVID-19 Vaccines: Subgroup Disproportionality Analyses in VigiBase. Vaccines. 2021;9:1022. doi: 10.3390/vaccines9091022. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Not applicable.